Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
**PANAF-Premium** is a polyvalent, enzyme-refined equine snake antivenom for treatment of clinically significant snakebite envenoming in sub-Saharan Africa. It contains purified equine immunoglobulin F(ab′)2 fragments raised against African snake venoms and is supplied as a lyophilized antiserum with sterile water for injection. The product is administered intravenously after reconstitution and neutralizes circulating venom toxins from medically important African *Bitis*, *Echis*, *Naja*, and *Dendroaspis* species. It is manufactured by Premium Serums & Vaccines and has received a WHO risk-benefit recommendation for specified sub-Saharan African snake species; a Phase IV study in northern Cameroon evaluated post-marketing safety and effectiveness. ([extranet.who.int](https://extranet.who.int/prequal/sites/default/files/document_files/PANAF-Premium%20single%20vial%2001032023.pdf))
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on PANAF-Premium.